• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Motif Neurotech Raises $18.75M for Implantable Device for Treatment-Resistant Depression

by Fred Pennic 01/26/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Motif Neurotech Raises $18.75M for Implantable Device for Treatment-Resistant Depression

What You Should Know:

– Motif Neurotech, a pioneer in minimally-invasive bioelectronics for mental health, announced today an impressive $18.75 million Series A funding round. Led by Arboretum Ventures, the investment saw participation from prominent players like KdT Ventures, Satori Neuro, and Dolby Family Ventures, alongside existing supporters Divergent Capital and PsyMed Ventures.

– Motif Neurotech’s innovative approach represents a potential paradigm shift in mental health treatment. By leveraging the power of bioelectronics, they aim to offer a safer, more targeted, and potentially more effective option for patients suffering from TRD.

Hope for Millions Struggling with TRD

TRD, a form of major depressive disorder unresponsive to traditional medications, affects millions worldwide. It can be a debilitating condition, leaving patients feeling hopeless and isolated. Motif’s DOT microstimulator offers a glimmer of hope, designed to precisely stimulate specific brain circuits linked to depression, restoring healthy activity and alleviating symptoms.

Precision Stimulation for Healthy Brain Circuitry

The DOT microstimulator is a pea-sized marvel, implanted during a minimally-invasive 20-minute outpatient procedure. It wirelessly transmits stimulation signals, allowing for at-home therapy and personalized treatment adjustments. This innovative approach offers several advantages over traditional deep brain stimulation (DBS) techniques:

  • Minimally invasive: No bulky electrodes or wires, reducing potential complications.
  • Precise stimulation: Targets specific brain circuits, minimizing side effects.
  • Wireless and rechargeable: Convenient for patients and adaptable to individual needs.

Expansion Plans

The Series A funding empowers Motif to:

  • Advance clinical development: Conduct large-scale studies to validate the DOT microstimulator’s efficacy and safety.
  • Refine the technology: Enhance the device’s functionality and user experience.
  • Scale production and distribution: Make the DOT microstimulator accessible to more patients with TRD.

“This investment is a testament to the immense potential of our technology to revolutionize the treatment of TRD,” said Jacob Robinson, CEO & Founder of Motif Neurotech. “We are incredibly grateful for the support of our investors and excited to bring hope and relief to millions suffering from this debilitating condition.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Digital Health Funding Q3 2025: Choppy Undercurrents Beneath a Steady Surface

Featured Interview

ConcertAI VP Shares View on AI Hallucinations and the Fabricated Data Crisis in Scientific Publishing

Most-Read

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |